Duovir N Tablets

Mili Healthcare
  • Category :
  • Manufacturer : Cipla Ltd.
  • Description : Additional important information regarding the use of nevirapine for the treatment of HIV infection: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, DUOVIR-N Tablets should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm 3 or in adult males with CD4+ cell counts greater than 400 cells/mm 3 unless the benefit outweighs the risk (see WARNINGS AND PRECAUTION ). The 14-day lead-in period with nevirapine 200 mg daily dosing has been demonstrated to reduce the frequency of rash (see WARNINGS AND PRECAUTIONS; DOSAGE AND ADMINISTRATION ). If rash persists beyond the 14 day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once daily dosing regimen should not be continued beyond 28 days, after which an alternative regimen should be sought.
  • Indication : DUOVIR-N Tablets are indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg b.i.d., and have demonstrated adequate tolerability to nevirapine. DUOVIR-N Tablets contains Zidovudine 300mg, Lamivudine 150mg and Nevirapine 200mg
  • Strength : 300 mg + 150 mg + 200 mg
  • The content presented on the MILI HEALTHCARE website is presented solely for informational purposes.

Cipla Ltd, Glaxo SmithKline (GSK), Ranbaxy, Dr. Reddy's, Zydus Cadila, FDC Ltd, Abbott Laboratories, Johnson & Johnson, Organon, Allergan, Glenmark, German Remedies, Lupin, Serdia, Galderma, Alkem, Alembic, Nicholas Piramal, Martin & Harris, IPCA, RPG Life Sciences, Franco Indian, Wockhardt, Merind.